TrialNCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
- Last update posted
- 09/04/2026
- Start
- 03/09/2026
- Sponsor
- Eli Lilly and Company
- Specialties
- oncology
Conditions: Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
Brief summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.